Pre-eclampsia and risk of later kidney disease: nationwide cohort study

Jonas H Kristensen,1 Saima Basit,1 Jan Wohlfahrt,1 Mette Brimnes Damholt,2 Heather A Boyd1

ABSTRACT

OBJECTIVE
To investigate associations between pre-eclampsia and later risk of kidney disease.

DESIGN
Nationwide register based cohort study.

SETTING
Denmark.

POPULATION
All women with at least one pregnancy lasting at least 20 weeks between 1978 and 2015.

MAIN OUTCOME MEASURE
Hazard ratios comparing rates of kidney disease between women with and without a history of pre-eclampsia, stratified by gestational age at delivery and estimated using Cox regression.

RESULTS
The cohort consisted of 1 072 330 women followed for 19 994 470 person years (average 18.6 years/woman). Compared with women with no previous pre-eclampsia, those with a history of pre-eclampsia were more likely to develop chronic renal conditions: hazard ratio 3.93 (95% confidence interval 2.90 to 5.33, for early preterm pre-eclampsia (delivery <34 weeks); 2.81 (2.13 to 3.71) for late preterm pre-eclampsia (delivery 34-36 weeks); 2.27 (2.02 to 2.55) for term pre-eclampsia (delivery ≥37 weeks). In particular, strong associations were observed for chronic kidney disease, hypertensive kidney disease, and glomerular/proteinuric disease. Adjustment for cardiovascular disease and hypertension only partially attenuated the observed associations. Stratifying the analyses on time since pregnancy showed that associations between pre-eclampsia and chronic kidney disease and glomerular/proteinuric disease were much stronger within five years of the latest pregnancy (hazard ratio 6.11 (3.84 to 9.72) and 4.77 (3.88 to 5.86), respectively) than five years or longer after the latest pregnancy (2.06 (1.69 to 2.50) and 1.50 (1.19 to 1.88). By contrast, associations between pre-eclampsia and acute renal conditions were modest.

CONCLUSION
Pre-eclampsia, particularly early preterm pre-eclampsia, was strongly associated with several chronic renal disorders later in life. More research is needed to determine which women are most likely to develop kidney disease after pre-eclampsia, what mechanisms underlie the association, and what clinical follow-up and interventions (and in what timeframe post-pregnancy) would be most appropriate and effective.

Introduction
Pre-eclampsia is a systemic disorder of pregnancy characterised by various manifestations of organ dysfunction, chief among them hypertension and proteinuria, a sign of renal dysfunction.1 Although a certain degree of glomerular endotheliosis may not be uncommon even in healthy pregnant women,2 women with pre-eclampsia show signs of severe endothelial dysfunction in the glomerulus, changes in expression of podocyte associated proteins, and possibly even podocyte injury and loss.2-5 In addition to significant proteinuria, women with pre-eclampsia can develop impaired glomerular filtration and, in severe cases, renal failure.

Although the renal dysfunction associated with pre-eclampsia is well documented, the repercussions of pre-eclampsia for later renal function and disease remain unclear. The potential renal consequences of pre-eclampsia include acute renal dysfunction that develops during the affected pregnancy and does not resolve after delivery, a lowering of the threshold for acute renal dysfunction given renal insult in the years after delivery, and increased susceptibility to later chronic kidney disease. Owing to large between study variation in sample size, length of follow-up, time since affected pregnancy, and endpoint definition, this is probably due to considerable between study differences in sample size, length of follow-up, time since affected pregnancy, and endpoint definition. Studies investigating associations between pre-eclampsia and both chronic kidney disease and clinical markers of renal dysfunction have produced highly variable results.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Epidemiological studies have documented strong associations between pre-eclampsia and end stage renal disease.

Studies investigating associations between pre-eclampsia and both chronic kidney disease and clinical markers of renal dysfunction have produced highly variable results.

This is probably due to considerable between study differences in sample size, length of follow-up, time since affected pregnancy, and endpoint definition.

WHAT THIS STUDY ADDS

History of pre-eclampsia (particularly early preterm pre-eclampsia) was associated with greatly increased risks of chronic kidney disease, hypertensive kidney disease, and glomerular and proteinuric disease later in life.

By contrast, pre-eclampsia was only modestly associated with acute kidney disease.

Associations between pre-eclampsia and chronic kidney disease and glomerular and proteinuric disease were especially strong within five years of the latest pregnancy.
be related to both kidney disease and hypertensive disease, or other conditions known or suspected to cause cardiovascular disease, hypertension, autoimmune defects or insufficiency and women registered with or hereditary conditions associated with kidney disease. We also excluded women who were ever registered in the National Patient Register with congenital defects or insufficiency.

Analyses) were excluded from the cohort (fig 1).

We identified women who had pre-eclampsia, eclampsia, or the HELLP syndrome during the study period by using the National Patient Register; we grouped eclampsia and the HELLP syndrome with pre-eclampsia because these conditions are rare in Denmark. Pre-eclampsia diagnoses in the National Patient Register have previously been validated against the American Congress of Obstetricians and Gynecologists’ 2002 definitions, with good results.

To ensure that registered diagnoses reflected true instances of pre-eclampsia, we required women to have at least one diagnosis registered in the period from one month before delivery to seven days postpartum. We did not consider women with diagnoses registered earlier in pregnancy without a confirmatory diagnosis registered in this period to have had pre-eclampsia.

As, by definition, a diagnosis of pre-eclampsia is not assigned before 20 weeks’ gestation, we considered only diagnoses registered after this point. (See supplementary methods for the relevant international classification of disease (ICD) codes.) We treated only diagnoses registered during the follow-up period. However, once she had experienced pre-eclampsia, she contributed all remaining person time to the exposed group, regardless of any later normotensive pregnancies.

Methods
Study cohort
Using the Medical Birth Register and the National Patient Register, we identified all women with at least one pregnancy lasting at least 20 weeks and ending in live birth or stillbirth in Denmark during the period January 1978 to October 2015. Women registered in the National Patient Register with kidney disease before the start of follow-up (see Statistical analyses) were excluded from the cohort (fig 1). We also excluded women who were ever registered in the National Patient Register with congenital or hereditary conditions associated with kidney disease.

We considered a woman to have incident post-pregnancy kidney disease if she received a first diagnosis of kidney disease in the National Patient Register or the Causes of Death Register more than three months after delivery. Diagnoses of moderate and severe renal disease in the National Patient Register, including hypertensive kidney disease, most glomerular disease diagnoses, chronic tubulointerstitial nephritis, and renal failure, have previously been validated. Although the study was small (50 records validated), diagnoses from 100% of the charts had been correctly coded and registered.

Because pre-eclampsia often involves kidney dysfunction, which in a proportion of women is severe and may even warrant a diagnosis of acute kidney failure, we could not disentangle incident kidney disease diagnoses assigned during pregnancy or shortly after delivery from diagnoses recorded to describe morbidity associated with pre-eclampsia. Consequently, our study focused only on diagnoses registered more than three months after delivery, under the assumption that any transient kidney dysfunction related to pre-eclampsia should have subsided by this point, any persistent problems would be registered again when postpartum kidney dysfunction would be documented again.
function did not normalise, and diagnoses registered for the first time more than three months after delivery were unlikely to describe morbidity related to pre-eclampsia. We considered all kidney disease registered in the peripartum period (20 weeks before delivery to three months postpartum) to be potentially pregnancy related and not of interest. Women registered with kidney disease within three months of their first delivery in the study period (that is, before the start of follow-up) were excluded from the study cohort; if a woman was registered with kidney disease in the peripartum period of any subsequent pregnancy, her follow-up ended.

In our cohort, 85% of women registered as having kidney disease had either a functional diagnosis or an aetiological diagnosis, but not both. (This is probably because establishing an aetiological diagnosis often requires a biopsy, which is not always feasible, resulting in assignment of a functional diagnosis instead. Conversely, when an aetiological diagnosis can be established, a functional diagnosis becomes redundant.) Consequently, our outcome categories included four functional categories (acute kidney failure, chronic kidney disease, hypertensive kidney disease, and unspecified kidney disease) and five aetiological categories (glomerular and proteinuric disease, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, unspecified tubulointerstitial nephritis, and other kidney disease), as well as a separate group containing kidney disease due to external causes or secondary to known disease (for example, obstructive uropathy, nephropathy due to external toxicity, diabetic kidney disease). (See supplementary methods for the ICD codes used to define each category.) Women with both a functional diagnosis and an aetiological diagnosis were classified on the basis of the first registered diagnosis.

In our analyses, before considering the individual categories, we examined two broad outcome categories: acute renal disorders, which included acute kidney failure and acute tubulointerstitial nephritis; and chronic renal disorders, which encompassed chronic kidney disease, hypertensive kidney disease, chronic tubulointerstitial nephritis, and glomerular and proteinuric diseases.

**Statistical analyses**

We followed women from three months after their first delivery in the study period until the first of diagnosis of kidney disease, death, emigration, designated “missing” in the Danish Civil Registration System,22 pregnancy with unknown gestational length, or 31 December 2015. Women with more than one pregnancy during the follow-up period contributed follow-up time during and after all pregnancies subsequent to the first, but the peripartum time associated with any subsequent pregnancies (20 weeks before delivery to three months after delivery) was excluded from the analyses. If a woman developed kidney disease in the peripartum period, follow-up ended.

Using Cox regression, we first estimated hazard ratios for acute renal disorders in aggregate and chronic renal disorders in aggregate, comparing women with and without a history of pre-eclampsia. We then estimated separate hazard ratios for individual kidney disease categories by using a competing risks approach—that is, in the analysis of each specific category, follow-up stopped when a woman received her first diagnosis of kidney disease regardless of type of kidney disease, but only a diagnosis in the specific disease category being analysed counted as a case.

In all models, we used age as the underlying time and stratified the baseline hazards by parity (one, two, or three or more live births and/or stillbirths; time dependent variable) and maternal birth year (five year intervals; time independent variable). This ensured that we compared rates in women of the same age, birth cohort, and parity; including maternal birth year also helped to account for possible time trends in pre-eclampsia and kidney disease diagnoses. All analyses were also adjusted for history of gestational hypertension and history of shortest gestation (<29 weeks, 30-31 weeks, 32-33 weeks, one week intervals from 34 weeks to 41 weeks, ≥42 weeks; time dependent variable). We considered a woman to have gestational hypertension in a given pregnancy if she was registered during the pregnancy.
with gestational hypertension in the period from one month before delivery to seven days postpartum without also receiving a diagnosis of pre-eclampsia. As we did for pre-eclampsia, we treated history of gestational hypertension as a time dependent variable, such that a woman could contribute with both affected and unaffected pregnancies, but once she had experienced gestational hypertension she contributed all remaining person time to the affected group, regardless of any later normotensive pregnancies.

Preterm delivery has been associated with later risk of kidney biopsy, and it was associated with increased risks of kidney disease in our data. Therefore, we stratified all our main analyses by gestational age at delivery (<34 weeks, 34-36 weeks, ≥37 weeks), so that women with a history of pre-eclampsia who delivered preterm would be compared with women with no history of pre-eclampsia who also delivered preterm. (See supplementary figure A for details of the construction of the time dependent variable used in the stratified analyses that reflected both history of pre-eclampsia and gestational age at delivery). We used an interaction test to evaluate differences in hazard ratios by gestational age at delivery.

To explore the importance of time since the latest pregnancy, we did additional analyses to estimate separate hazard ratios for time since latest pregnancy less than five years and five years or longer. Owing to power considerations, these analyses could not be stratified on gestational age at delivery. We also explored the effect of adjusting for additional covariates that might be either confounders or mediators of the associations of interest. These covariates included autoimmune and inflammatory conditions, cardiovascular disease, diabetes, and hypertension, all treated as time dependent variables (see supplementary methods for definitions of each group). Therefore, if a woman did not have, for example, diabetes at the start of follow-up but was later diagnosed as having diabetes, she contributed person time as non-diabetic from the start of follow-up until her diagnosis of diabetes; thereafter, she contributed all remaining person time until the end of follow-up as diabetic.

We evaluated potential violations of the proportional hazards assumption by plotting martingale residuals against attained age. We used SAS statistical software, version 9.4, for all analyses.

**Patient and public involvement**

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. Direct dissemination of the study results to study participants is not possible given the size of the cohort and length of the study period.

**Results**

The study cohort consisted of 1072330 women with 2046984 pregnancies ending in live birth or stillbirth during the study period. The women were followed for 19994470 person years (average 18.6 years per woman). During follow-up, 14816 women developed kidney disease (7320 acute renal disorders (3.6/100000 person years), 3901 chronic renal disorders (1.9/100000 person years), 1470 other specified renal disorders (0.7/100000 person years), and 2125 unspecified renal disorders (1.1/100000 person years)). Of these women, 1062 (7.2%) had a history of pre-eclampsia. Only 55503 women (5.2%) were lost to follow-up; most of these women either moved abroad (n=26835) or died (n=28161). Table 1 shows maternal age and parity at first pregnancy in the study period, by pre-eclampsia status and timing of delivery.

Our results showed modest associations between pre-eclampsia later in pregnancy (late preterm and term) and later acute renal disorders, but no statistical support for an association with early preterm pre-eclampsia (table 2). However, few instances of acute renal disorders occurred among women delivering preterm, particularly among women who also had pre-eclampsia, resulting in wide confidence intervals around the estimates for early preterm pre-eclampsia (table 2).

By contrast, women with a history of pre-eclampsia had at least twice the risk of later chronic renal disorders overall, compared with women who delivered at the same gestational age but never had pre-eclampsia (table 3). Magnitudes of association were larger for earlier gestational age at delivery (P<0.001), with the risk of any chronic renal disorder almost quadrupling for women with a history of early preterm pre-eclampsia. We observed a similar pattern of association for three of the four subtypes of chronic renal disorder, although only the pattern for glomerular and proteinuric disease was statistically significant (P<0.001) (table 3). Few women were diagnosed as having chronic tubulointerstitial nephritis during follow-up, making the drawing of conclusions about this type of chronic renal disorder difficult. Patterns of association for other and unspecified kidney disease were similar to those observed for the chronic renal disorders, whereas the hazard ratios for unspecified tubulointerstitial nephritis more closely resembled the estimates for acute renal disorders (supplementary table A).

When we examined the effect of time since latest pregnancy on our results, pre-eclampsia was especially strongly associated with the risk of chronic kidney disease and glomerular and proteinuric disease within five years of the latest pregnancy (hazard ratio 6.11 (95% confidence interval 3.84 to 9.72) and 4.77 (3.88 to 5.86), respectively) (fig 2). Thereafter, the strength of the associations decreased (chronic kidney disease, P for difference<0.001; glomerular and proteinuric disease, P for difference<0.001). However, five years or more after the latest pregnancy, women with a history of pre-eclampsia still had risks of chronic kidney disease and glomerular and proteinuric disease that were 100% and 50% higher than the risks observed.
in women with no history of pre-eclampsia (hazard ratio 2.06 (1.69 to 2.50) and 1.50 (1.19 to 1.88), respectively). By contrast, hazard ratios for the acute renal disorders and the other subtypes of chronic renal disorder seemed to be more stable over time (fig 2 and supplementary table B).

Adjustment for diabetes and autoimmune/inflammatory disease diagnosed during follow-up had little effect on our estimates (table 4). On the other hand, adjustment for post-pregnancy cardiovascular disease and hypertension decreased the strength of the observed associations by 20-30% (table 4).

### Discussion

Our study found strong, statistically significant associations between pre-eclampsia and later chronic kidney disease, hypertensive kidney disease, and glomerular and proteinuric disease, with stronger associations for earlier onset of pre-eclampsia. The associations between pre-eclampsia and the risks of glomerular and proteinuric disease and chronic kidney disease were particularly strong in the five years after a pregnancy, whereas time since pregnancy did not seem to modify the associations with other types of kidney disease. Adjustment for hypertension and cardiovascular disease diagnosed during the follow-up period diminished, but could not eliminate, the observed associations with chronic renal disorders, suggesting that the observed associations were only partially mediated by these factors. Conversely, adjustment for diabetes and autoimmune and inflammatory conditions had very little effect on the magnitude of the estimates.

### Strengths and potential limitations of study

Our use of a cohort including all women nationwide who were pregnant during a 38 year period minimised the possibility of selection bias and provided us with the power to examine the effect of timing of onset of pre-eclampsia, time since pregnancy, and specific kidney disease subtypes. Furthermore, the size of our cohort allowed us to do analyses stratified by gestational age at delivery and to determine that the apparent association between pre-eclampsia and kidney disease was not simply attributable to the preterm delivery often associated with pre-eclampsia but that pre-eclampsia had an added effect. Use of diagnoses recorded in national registers (with mandatory reporting) eliminated the possibility of recall bias and helped to standardise outcome definitions. By applying Cox regression, we were able to accommodate variable follow-up and time dependent covariates that have challenged previous studies.

Although the sensitivity of pre-eclampsia diagnoses recorded in the National Patient Register has been found to be only moderate (69%), their specificity is very high (>99%). Consequently, although a proportion of affected women may not have had their pre-eclampsia registered, somewhat diluting our results, the risk of bias due to unaffected women being classified as having pre-eclampsia was likely negligible. As might be expected in a study spanning decades, definitions

### Table 1 | Maternal age and parity at first pregnancy in study period resulting in live birth or stillbirth, by pre-eclampsia status and timing of delivery, Denmark, 1978-2015. Values are numbers (percentages)

<table>
<thead>
<tr>
<th>Parity</th>
<th>Total</th>
<th>Term</th>
<th>Late preterm</th>
<th>Early preterm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2651 (0.2)</td>
<td>33 524 (3.1)</td>
<td>11 790 (1.7)</td>
<td>41 705 (3.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parity</th>
<th>Total</th>
<th>Term</th>
<th>Late preterm</th>
<th>Early preterm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2651 (0.2)</td>
<td>33 524 (3.1)</td>
<td>11 790 (1.7)</td>
<td>41 705 (3.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parity</th>
<th>Total</th>
<th>Term</th>
<th>Late preterm</th>
<th>Early preterm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2651 (0.2)</td>
<td>33 524 (3.1)</td>
<td>11 790 (1.7)</td>
<td>41 705 (3.9)</td>
</tr>
</tbody>
</table>

### Table 2 | Hazard ratios for acute renal disorders overall and by subtype, by history of pre-eclampsia (PE) and timing of delivery, Denmark, 1978-2015

<table>
<thead>
<tr>
<th>Timing of delivery</th>
<th>History of PE</th>
<th>Person years (×10⁶)</th>
<th>Any acute renal disorder*</th>
<th>Acute kidney failure</th>
<th>Acute tubulointerstitial nephritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early preterm</td>
<td>Yes 54.0</td>
<td>29 0.0 (0.72 to 1.56)</td>
<td>0.49 (0.12 to 2.02)</td>
<td>1.17 (0.78 to 1.75)</td>
<td></td>
</tr>
<tr>
<td>No 449.1</td>
<td>215 0.1 (reference)</td>
<td>36 1.0 (reference)</td>
<td>179 1.0 (reference)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late preterm</td>
<td>Yes 90.7</td>
<td>54 1.33 (1.00 to 1.76)</td>
<td>0.72 (0.29 to 1.78)</td>
<td>1.46 (1.08 to 1.96)</td>
<td></td>
</tr>
<tr>
<td>No 1027.7</td>
<td>449 1.0 (reference)</td>
<td>77 1.0 (reference)</td>
<td>372 1.0 (reference)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Term</td>
<td>Yes 760.4</td>
<td>313 1.12 (1.00 to 1.28)</td>
<td>0.59 (1.21 to 2.05)</td>
<td>254 1.05 (0.93 to 1.19)</td>
<td></td>
</tr>
<tr>
<td>No 17 612.6</td>
<td>6260 1.0 (reference)</td>
<td>814 1.0 (reference)</td>
<td>5446 1.0 (reference)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


*Includes acute kidney failure and acute tubulointerstitial nephritis.
†All hazard ratios are adjusted for maternal age (underlying time in Cox model), maternal birth year, parity, history of gestational hypertension, and history of shortest gestation.
‡Under current Danish and European data protection laws, exact numbers cannot be given because one cell contains <5 women.

### Table 3 | Hazard ratios for acute renal disorders overall and by subtype, by history of pre-eclampsia (PE) and timing of delivery, Denmark, 1978-2015

<table>
<thead>
<tr>
<th>Timing of delivery</th>
<th>History of PE</th>
<th>Person years (×10⁶)</th>
<th>Any acute renal disorder*</th>
<th>Acute kidney failure</th>
<th>Acute tubulointerstitial nephritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early preterm</td>
<td>Yes 54.0</td>
<td>29 0.0 (0.72 to 1.56)</td>
<td>0.49 (0.12 to 2.02)</td>
<td>1.17 (0.78 to 1.75)</td>
<td></td>
</tr>
<tr>
<td>No 449.1</td>
<td>215 0.1 (reference)</td>
<td>36 1.0 (reference)</td>
<td>179 1.0 (reference)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late preterm</td>
<td>Yes 90.7</td>
<td>54 1.33 (1.00 to 1.76)</td>
<td>0.72 (0.29 to 1.78)</td>
<td>1.46 (1.08 to 1.96)</td>
<td></td>
</tr>
<tr>
<td>No 1027.7</td>
<td>449 1.0 (reference)</td>
<td>77 1.0 (reference)</td>
<td>372 1.0 (reference)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Term</td>
<td>Yes 760.4</td>
<td>313 1.12 (1.00 to 1.28)</td>
<td>0.59 (1.21 to 2.05)</td>
<td>254 1.05 (0.93 to 1.19)</td>
<td></td>
</tr>
<tr>
<td>No 17 612.6</td>
<td>6260 1.0 (reference)</td>
<td>814 1.0 (reference)</td>
<td>5446 1.0 (reference)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


*Includes acute kidney failure and acute tubulointerstitial nephritis.
†All hazard ratios are adjusted for maternal age (underlying time in Cox model), maternal birth year, parity, history of gestational hypertension, and history of shortest gestation.
‡Under current Danish and European data protection laws, exact numbers cannot be given because one cell contains <5 women.
Table 3 | Hazard ratios for chronic renal disorders overall and by subtype, by history of pre-eclampsia and timing of delivery, Denmark, 1978-2015

<table>
<thead>
<tr>
<th>Timing of delivery</th>
<th>History of PE</th>
<th>Person years (× 10^3)</th>
<th>Any chronic renal disorder</th>
<th>Chronic kidney disease</th>
<th>Hypertensive kidney disease</th>
<th>Chronic tubulointerstitial nephritis</th>
<th>Glomerular and proteinuric diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early preterm</td>
<td>Yes</td>
<td>54.0</td>
<td>62 3.93 (2.90 to 5.33)</td>
<td>18 2.90 (1.70 to 4.96)</td>
<td>9 4.19 (1.86 to 9.42)</td>
<td>5 2.91 (1.06 to 8.11)</td>
<td>30 5.34 (3.36 to 8.46)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>449.1</td>
<td>130 1 (reference)</td>
<td>53 1 (reference)</td>
<td>17 1 (reference)</td>
<td>14 1 (reference)</td>
<td>46 1 (reference)</td>
</tr>
<tr>
<td>Late preterm</td>
<td>Yes</td>
<td>90.7</td>
<td>63 2.81 (2.13 to 3.71)</td>
<td>17 2.24 (1.33 to 3.78)</td>
<td>17 1.39 (1.91 to 7.13)</td>
<td>* 0.93 (0.22 to 3.95)</td>
<td>32 3.40 (2.28 to 5.06)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>1027.7</td>
<td>247 1 (reference)</td>
<td>85 1 (reference)</td>
<td>35 1 (reference)</td>
<td>23 1 (reference)</td>
<td>104 1 (reference)</td>
</tr>
<tr>
<td>Term</td>
<td>Yes</td>
<td>760.4</td>
<td>317 2.27 (2.02 to 2.55)</td>
<td>104 2.27 (1.85 to 2.78)</td>
<td>64 3.06 (2.34 to 3.99)</td>
<td>15 1.48 (0.88 to 2.51)</td>
<td>134 2.14 (1.79 to 2.56)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>17612.6</td>
<td>3082 1 (reference)</td>
<td>1008 1 (reference)</td>
<td>432 1 (reference)</td>
<td>234 1 (reference)</td>
<td>1408 1 (reference)</td>
</tr>
</tbody>
</table>

P-value for homogeneity: 0.69 0.70 0.38 <0.001

HR= Hazard ratio; PE = pre-eclampsia.

Early preterm: delivery <34 weeks.
Late preterm: delivery 34-36 weeks.
Term: delivery ≥37 weeks.

*All hazard ratios are adjusted for maternal age (underlying time in Cox model), maternal birth year, parity, history of gestational hypertension, and history of shortest gestation.
†Under current Danish and European data protection laws, exact numbers cannot be given because one cell contains <5 women.

of pre-eclampsia have evolved since the beginning of our study period. Of particular relevance to our study, proteinuria (a sign of kidney involvement) has no longer been required for a diagnosis of pre-eclampsia according to internationally accepted guidelines since 2014. However, our follow-up period ended in 2015, only a year after this change came into effect. Furthermore, our study was based on ICD-8 and ICD-10 codes, both of which required proteinuria for a diagnosis of pre-eclampsia (see supplementary methods for definitions). Proteinuria was therefore a fairly universal feature of pre-eclampsia throughout our study period; other changes to diagnostic criteria were unlikely to have produced sufficient heterogeneity in the exposure to have a meaningful effect on the observed associations.

Although the validity of diagnoses of moderate and severe renal disease in the National Patient Register is excellent,21 the sensitivity of the registers for individual diagnoses may not always be high, particularly for milder degrees of renal impairment, which are known to be underreported in connection with other comorbidities such as diabetes. However, the specificity of registered diagnoses of renal disease is likely to be high, particularly for aetiological diagnoses such as glomerular disease, which are not typically assigned without confirmation by biopsy, and for chronic kidney disease, which by definition requires specialist intervention. Any misclassification of outcome is likely to have been non-differential, as postpartum kidney function in women who previously had pre-eclampsia has not been much studied and registration of kidney disorders would not be expected to depend on exposure status. Consequently, under-registration of kidney disease outcomes is unlikely to have biased our results substantially.

The acute renal dysfunction diagnoses included in ICD-8 and ICD-10 changed very little over the study period. Of particular relevance to our study, the acute renal dysfunction diagnoses included in ICD-8 and ICD-10 have on 18 September 2021 by guest. Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l1516 on 29 April 2019. Downloaded from http://www.bmj.com/ on 18 September 2021 by guest. Protected by copyright.
period. However, as with pre-eclampsia, kidney disease paradigms have evolved. In particular, the concept of acute kidney injury has emerged in the past 10-15 years, and KDIGO published guidelines for staging acute kidney injury in 2012.21 Acute kidney injury and its staging are not yet implemented in the ICD system; of particular note, the early stages of acute kidney injury have no direct equivalent in ICD-10 (the version currently used in Denmark). Consequently, our use of the ICD system will have resulted in an overall underestimation of the occurrence of acute renal dysfunction as defined by the KDIGO system. This underestimation will have been most pronounced for early stages of acute kidney injury, about which little can be inferred from our findings. By contrast, any underestimation of the rates of severe, clinically important acute renal dysfunction is likely to have been negligible, as these conditions are diagnosed and treated in the hospital setting and captured by ICD codes.

Changing definitions and diagnostics for chronic kidney disease have mostly affected our ability to subclassify the condition. Whereas chronic kidney disease was previously classified clinically as mild, moderate, or severe, it is now staged from 1 to 5.6 However, the overall definition of chronic kidney disease covered approximately the same group of patients throughout the study period, so changes to definitions and diagnostic criteria are not likely to have had a large effect on our findings.

Pre-eclampsia is strongly associated with later cardiovascular disease, hypertension, and diabetes,28-30 all of which are known risk factors for chronic kidney disease and could therefore be suspected of mediating the observed associations. However, our results indicated that comorbid conditions, cardiovascular disease and hypertension in particular, could only partially explain the observed associations, suggesting that at least part of the link between pre-eclampsia and chronic kidney disease might arise from common predisposing factors such as increased susceptibility to vascular endothelial dysfunction.

Obesity is associated with both pre-eclampsia and chronic kidney disease, but whether obesity might be an independent confounder of the observed associations after adjustment for cardiovascular disease and diabetes (with which it is strongly associated) is unclear. Of the studies that previously examined the association between pre-eclampsia and chronic kidney disease or end stage renal disease, three did not consider obesity important enough to adjust for it.11-13 Ayansina and colleagues observed a decrease in magnitude of the association when they adjusted for body mass index, socioeconomic status, and smoking, but they did not also adjust for cardiovascular disease, diabetes, and hypertension.14 We lacked information on pre-pregnancy body mass index for most of our cohort, and information on body mass index in non-pregnant individuals is not registered; therefore, we were unable to adjust for the potential influence of obesity. We also cannot rule out the possibility of residual confounding by other unmeasured covariates. Finally, we note that our cohort was comprised predominantly of white European women, which may limit the generalisability of our findings to other populations with different covariate distributions.

Comparison with other studies
Previous studies of overt renal disease after hypertensive disorders of pregnancy have largely focused on chronic kidney disease, particularly end stage renal disease. 

Table 4 | Hazard ratios for chronic kidney disorders overall by history of pre-eclampsia and timing of delivery, with additional adjustment for new onset  

<table>
<thead>
<tr>
<th>Timing of delivery</th>
<th>No additional adjustment</th>
<th>Additionally adjusted for:</th>
</tr>
</thead>
</table>
|                    | Autoimmune disease | Cardiovascular disease | Diabetes | Hypertension†  
| Early preterm | 3.93 (2.90 to 5.33) | 3.88 (2.86 to 5.26) | 2.89 (2.13 to 3.92) | 3.77 (2.78 to 5.11) | 2.84 (2.02 to 4.01)  
| Late preterm | 2.81 (2.13 to 3.71) | 2.74 (2.07 to 3.61) | 2.28 (1.73 to 3.02) | 2.69 (2.04 to 3.56) | 1.83 (1.32 to 2.55)  
| Term | 2.27 (2.02 to 2.55) | 2.23 (1.98 to 2.50) | 1.88 (1.67 to 2.12) | 2.11 (1.87 to 2.37) | 1.72 (1.51 to 1.96)  


*All hazard ratios are adjusted for maternal age (underlying time in the Cox model), maternal birth year, parity, history of gestational hypertension, and history of shortest gestation.

†Based on smaller number of events than other adjusted analyses (pre-eclampsia PE) with early preterm delivery: 48, no PE; early preterm delivery: 104; PE with late preterm delivery: 43; no PE, late preterm delivery: 201; PE with term delivery: 259; no PE, term delivery: 2601 because information on use of antihypertensive drugs was available only from 1994. Therefore, women diagnosed as having kidney disease or for whom follow-up ended for other reasons before 1994 (eg, death, emigration) were excluded from analyses adjusted for hypertension.
pre-eclampsia regardless of the timing of onset of pre-eclampsia, but that women who had preterm pre-eclampsia were especially at risk. Furthermore, we showed that the risks of post-pregnancy chronic kidney disease and glomerular and proteinuric disease were greatest in the five years after a pregnancy, rather than decades later.

Our findings for the glomerular and proteinuric diseases are consistent with the results of other studies suggesting that microalbuminuria and possibly reduced glomerular filtration rate are more prevalent among women with previous pre-eclampsia than among women who had healthy pregnancies.7 10 Interestingly, we found that women with a history of pre-eclampsia were at greatest risk of glomerular and proteinuric disease within five years of pregnancy.

Although acute kidney failure is a known complication of pre-eclampsia, particularly in developing countries,31 little is known about the relation between pre-eclampsia and incident acute renal disorders postpartum. We found evidence of only modest associations between pre-eclampsia and later acute renal disorders and then only for pre-eclampsia with onset later in pregnancy (later preterm and term pre-eclampsia). However, very few women with a history of preterm pre-eclampsia developed acute renal disorders during the follow-up period, preventing us from drawing firm conclusions about whether an association exists between preterm pre-eclampsia and acute kidney disease and, if so, how strong such an association might be. Associations between pre-eclampsia and acute renal disorders may reflect shared susceptibility to both pathologies conferred by common risk factors. Alternatively, undetected pre-pregnancy acute kidney dysfunction in some women may have contributed to the observed associations. We also cannot exclude the possibility that the associations we observed between pre-eclampsia of later onset and acute renal disorders might have resulted from detection bias, as women with pre-eclampsia are intensively monitored after delivery to ensure that their creatinine concentrations return to normal. However, our decision to ignore diagnoses of kidney disease registered within three months of delivery and to stop follow-up for these women should have minimised the effect of any such bias.

Conclusions and policy implications

Our study results suggest that at least a subset of women with previous pre-eclampsia need clinical monitoring for kidney disease in the years immediately after pregnancy. Early detection of chronic renal disorders would allow for early intervention to delay disease progression32 33; ideally, detection of the antecedents of these disorders would permit implementation of measures to prevent the onset of chronic kidney disease entirely. However, more research is needed to determine which women are at greatest risk of kidney disease after pre-eclampsia, what mechanisms underlie the association, and therefore what follow-up and interventions (and in what timeframe post-pregnancy) would be most appropriate and effective.

Contributors: JHK conceived and designed the study, defined exclusion criteria and exposure, outcome, and covariate categories; interpreted the study findings, and drafted the manuscript. SB conceived and designed the study, acquired and analysed the data, interpreted the study findings, and critically reviewed the manuscript. JW designed the study, advised on selection and implementation of analytical methods, interpreted the study findings, and critically reviewed the manuscript. MBD conceived and designed the study, interpreted the study findings, and critically reviewed the manuscript. HAB conceived and designed the study, supervised and directed the conduct of the study, interpreted the study findings, and critically revised the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no other funding the criteria have been omitted. JK, SB, JW, and HAB had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. HAB is the guarantor.

Funding: This work was partially supported by the Danish Council for Independent Research (DFF-4092-00213). The Danish Council for Independent Research had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The researchers acted independently from the study sponsor in all aspects of this study.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: SB was supported by a grant from the Danish Council for Independent Research; no other support for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Studies based solely on data from the Danish national registers do not need approval from the Danish research bioethics committees, as study participants are never contacted, and consent is not required for the use of register information. The study’s use of register data was covered by the approval extended by the Danish Data Protection Agency to all register based studies conducted by Statens Serum Institut (approval No 2015-57-0102).

Data sharing: This study is based on Danish national register data. These data do not belong to the authors but to the Danish Ministry of Health, and the authors are not permitted to share them, except in aggregate (as, for example, in a publication). However, interested parties can obtain the data on which the study was based by submitting a research protocol to the Danish Data Protection Agency (Datatilsynet) and then, once Data Protection Agency permission has been received, applying to the Ministry of Health’s Research Service (Forskelservice) at forskelservice@ssi.dk.

Transparency: The manuscript’s guarantor (HAB) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


doi:10.1136/bmj.j1516 | BMJ 2019;365:j1516 | thebmj

Supplementary materials